Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

A porcine xenograft-derived bone scaffold is a biocompatible bone graft substitute: An assessment of cytocompatibility and the alpha-Gal epitope.

Bracey DN, Seyler TM, Jinnah AH, Smith TL, Ornelles DA, Deora R, Parks GD, Van Dyke ME, Whitlock PW.

Xenotransplantation. 2019 Jul 25:e12534. doi: 10.1111/xen.12534. [Epub ahead of print]

PMID:
31342586
3.

Zika virus as an oncolytic treatment of human neuroblastoma cells requires CD24.

Mazar J, Li Y, Rosado A, Phelan P, Kedarinath K, Parks GD, Alexander KA, Westmoreland TJ.

PLoS One. 2018 Jul 25;13(7):e0200358. doi: 10.1371/journal.pone.0200358. eCollection 2018.

5.

Parainfluenza Virus Infection Sensitizes Cancer Cells to DNA-Damaging Agents: Implications for Oncolytic Virus Therapy.

Fox CR, Parks GD.

J Virol. 2018 Mar 14;92(7). pii: e01948-17. doi: 10.1128/JVI.01948-17. Print 2018 Apr 1.

6.

Adjuvanting an inactivated influenza vaccine with flagellin improves the function and quantity of the long-term antibody response in a nonhuman primate neonate model.

Holbrook BC, D'Agostino RB Jr, Parks GD, Alexander-Miller MA.

Vaccine. 2016 Sep 7;34(39):4712-4717. doi: 10.1016/j.vaccine.2016.08.010. Epub 2016 Aug 8.

7.

Parainfluenza virus 5 upregulates CD55 expression to produce virions with enhanced resistance to complement-mediated neutralization.

Li Y, Johnson JB, Parks GD.

Virology. 2016 Oct;497:305-313. doi: 10.1016/j.virol.2016.07.030. Epub 2016 Aug 6.

8.

A Novel R848-Conjugated Inactivated Influenza Virus Vaccine Is Efficacious and Safe in a Neonate Nonhuman Primate Model.

Holbrook BC, Kim JR, Blevins LK, Jorgensen MJ, Kock ND, D'Agostino RB Jr, Aycock ST, Hadimani MB, King SB, Parks GD, Alexander-Miller MA.

J Immunol. 2016 Jul 15;197(2):555-64. doi: 10.4049/jimmunol.1600497. Epub 2016 Jun 8.

9.

Inclusion of Flagellin during Vaccination against Influenza Enhances Recall Responses in Nonhuman Primate Neonates.

Kim JR, Holbrook BC, Hayward SL, Blevins LK, Jorgensen MJ, Kock ND, De Paris K, D'Agostino RB Jr, Aycock ST, Mizel SB, Parks GD, Alexander-Miller MA.

J Virol. 2015 Jul;89(14):7291-303. doi: 10.1128/JVI.00549-15. Epub 2015 May 6.

10.

Nonhuman primate infants have an impaired respiratory but not systemic IgG antibody response following influenza virus infection.

Holbrook BC, Hayward SL, Blevins LK, Kock N, Aycock T, Parks GD, Alexander-Miller MA.

Virology. 2015 Feb;476:124-133. doi: 10.1016/j.virol.2014.12.007. Epub 2014 Dec 24.

11.

An AGM model for changes in complement during pregnancy: neutralization of influenza virus by serum is diminished in late third trimester.

Mayer AE, Parks GD.

PLoS One. 2014 Nov 19;9(11):e112749. doi: 10.1371/journal.pone.0112749. eCollection 2014.

12.

A novel factor I activity in Nipah virus inhibits human complement pathways through cleavage of C3b.

Johnson JB, Borisevich V, Rockx B, Parks GD.

J Virol. 2015 Jan 15;89(2):989-98. doi: 10.1128/JVI.02427-14. Epub 2014 Oct 29.

13.

Coinfection with Streptococcus pneumoniae negatively modulates the size and composition of the ongoing influenza-specific CD8⁺ T cell response.

Blevins LK, Wren JT, Holbrook BC, Hayward SL, Swords WE, Parks GD, Alexander-Miller MA.

J Immunol. 2014 Nov 15;193(10):5076-87. doi: 10.4049/jimmunol.1400529. Epub 2014 Oct 13.

14.

The neutralizing capacity of antibodies elicited by parainfluenza virus infection of African Green Monkeys is dependent on complement.

Mayer AE, Johnson JB, Parks GD.

Virology. 2014 Jul;460-461:23-33. doi: 10.1016/j.virol.2014.05.004. Epub 2014 May 29.

15.

An alphavirus-based adjuvant enhances serum and mucosal antibodies, T cells, and protective immunity to influenza virus in neonatal mice.

Khalil SM, Tonkin DR, Snead AT, Parks GD, Johnston RE, White LJ.

J Virol. 2014 Aug;88(16):9182-96. doi: 10.1128/JVI.00327-14. Epub 2014 Jun 4.

16.

The Bordetella pertussis Bps polysaccharide enhances lung colonization by conferring protection from complement-mediated killing.

Ganguly T, Johnson JB, Kock ND, Parks GD, Deora R.

Cell Microbiol. 2014 Jul;16(7):1105-18. doi: 10.1111/cmi.12264. Epub 2014 Feb 13.

17.

Paramyxovirus activation and inhibition of innate immune responses.

Parks GD, Alexander-Miller MA.

J Mol Biol. 2013 Dec 13;425(24):4872-92. doi: 10.1016/j.jmb.2013.09.015. Epub 2013 Sep 20. Review.

18.

Point mutations in the paramyxovirus F protein that enhance fusion activity shift the mechanism of complement-mediated virus neutralization.

Johnson JB, Schmitt AP, Parks GD.

J Virol. 2013 Aug;87(16):9250-9. doi: 10.1128/JVI.01111-13. Epub 2013 Jun 19.

19.

Incorporation of host complement regulatory proteins into Newcastle disease virus enhances complement evasion.

Biswas M, Johnson JB, Kumar SR, Parks GD, Elankumarana S.

J Virol. 2012 Dec;86(23):12708-16. doi: 10.1128/JVI.00886-12. Epub 2012 Sep 12. Erratum in: J Virol. 2013 Jan;87(2):1287. Subbiah, Elankumaran [corrected to Elankumarana, Subbiah].

20.

Mumps virus inhibits migration of primary human macrophages toward a chemokine gradient through a TNF-alpha dependent mechanism.

Briggs CM, Mayer AE, Parks GD.

Virology. 2012 Nov 10;433(1):245-52. doi: 10.1016/j.virol.2012.08.017. Epub 2012 Aug 28.

21.

A novel process for optimizing musculoskeletal allograft tissue to improve safety, ultrastructural properties, and cell infiltration.

Whitlock PW, Seyler TM, Parks GD, Ornelles DA, Smith TL, Van Dyke ME, Poehling GG.

J Bone Joint Surg Am. 2012 Aug 15;94(16):1458-67.

PMID:
22786867
22.

Virion-associated complement regulator CD55 is more potent than CD46 in mediating resistance of mumps virus and vesicular stomatitis virus to neutralization.

Johnson JB, Lyles DS, Alexander-Miller MA, Parks GD.

J Virol. 2012 Sep;86(18):9929-40. doi: 10.1128/JVI.01154-12. Epub 2012 Jul 3.

23.

Parainfluenza virus 5-based vaccine vectors expressing vaccinia virus (VACV) antigens provide long-term protection in mice from lethal intranasal VACV challenge.

Clark KM, Johnson JB, Kock ND, Mizel SB, Parks GD.

Virology. 2011 Oct 25;419(2):97-106. doi: 10.1016/j.virol.2011.08.005. Epub 2011 Aug 31.

24.

Interactions of human complement with virus particles containing the Nipah virus glycoproteins.

Johnson JB, Aguilar HC, Lee B, Parks GD.

J Virol. 2011 Jun;85(12):5940-8. doi: 10.1128/JVI.00193-11. Epub 2011 Mar 30.

25.

Activation of human macrophages by bacterial components relieves the restriction on replication of an interferon-inducing parainfluenza virus 5 (PIV5) P/V mutant.

Briggs CM, Holder RC, Reid SD, Parks GD.

Microbes Infect. 2011 Apr;13(4):359-68. doi: 10.1016/j.micinf.2010.12.005. Epub 2010 Dec 24.

26.

IFNgamma-producing, virus-specific CD8+ effector cells acquire the ability to produce IL-10 as a result of entry into the infected lung environment.

Palmer EM, Holbrook BC, Arimilli S, Parks GD, Alexander-Miller MA.

Virology. 2010 Sep 1;404(2):225-30. doi: 10.1016/j.virol.2010.05.004.

27.

Replication-independent activation of human plasmacytoid dendritic cells by the paramyxovirus SV5 Requires TLR7 and autophagy pathways.

Manuse MJ, Briggs CM, Parks GD.

Virology. 2010 Sep 30;405(2):383-9. doi: 10.1016/j.virol.2010.06.023. Epub 2010 Jul 6.

28.

Pivotal Advance: Nonfunctional lung effectors exhibit decreased calcium mobilization associated with reduced expression of ORAI1.

Arimilli S, Sharma SK, Yammani R, Reid SD, Parks GD, Alexander-Miller MA.

J Leukoc Biol. 2010 Jun;87(6):977-88. doi: 10.1189/jlb.0809575. Epub 2010 Jan 26.

29.

TLR3-dependent upregulation of RIG-I leads to enhanced cytokine production from cells infected with the parainfluenza virus SV5.

Manuse MJ, Parks GD.

Virology. 2010 Feb 5;397(1):231-41. doi: 10.1016/j.virol.2009.11.014. Epub 2009 Nov 30.

30.

Role for the paramyxovirus genomic promoter in limiting host cell antiviral responses and cell killing.

Manuse MJ, Parks GD.

J Virol. 2009 Sep;83(18):9057-67. doi: 10.1128/JVI.01055-09. Epub 2009 Jul 8.

31.

The paramyxoviruses simian virus 5 and mumps virus recruit host cell CD46 to evade complement-mediated neutralization.

Johnson JB, Grant K, Parks GD.

J Virol. 2009 Aug;83(15):7602-11. doi: 10.1128/JVI.00713-09. Epub 2009 May 20.

32.

Engineered expression of the TLR5 ligand flagellin enhances paramyxovirus activation of human dendritic cell function.

Arimilli S, Johnson JB, Clark KM, Graff AH, Alexander-Miller MA, Mizel SB, Parks GD.

J Virol. 2008 Nov;82(22):10975-85. doi: 10.1128/JVI.01288-08. Epub 2008 Sep 10.

33.
34.

Virus growth and antibody responses following respiratory tract infection of ferrets and mice with WT and P/V mutants of the paramyxovirus Simian Virus 5.

Capraro GA, Johnson JB, Kock ND, Parks GD.

Virology. 2008 Jul 5;376(2):416-28. doi: 10.1016/j.virol.2008.03.034. Epub 2008 May 5.

35.

Differential mechanisms of complement-mediated neutralization of the closely related paramyxoviruses simian virus 5 and mumps virus.

Johnson JB, Capraro GA, Parks GD.

Virology. 2008 Jun 20;376(1):112-23. doi: 10.1016/j.virol.2008.03.022. Epub 2008 Apr 28.

36.

Paramyxovirus-induced shutoff of host and viral protein synthesis: role of the P and V proteins in limiting PKR activation.

Gainey MD, Dillon PJ, Clark KM, Manuse MJ, Parks GD.

J Virol. 2008 Jan;82(2):828-39. Epub 2007 Oct 31.

37.
38.

TLR-4 and -6 agonists reverse apoptosis and promote maturation of simian virus 5-infected human dendritic cells through NFkB-dependent pathways.

Arimilli S, Johnson JB, Alexander-Miller MA, Parks GD.

Virology. 2007 Aug 15;365(1):144-56. Epub 2007 Apr 24.

39.

Distinct pathways for signaling maturation in macrophages and dendritic cells after infection with paramyxovirus simian virus 5.

Pejawar-Gaddy S, Gitiban-Vaghefi N, Parks GD, Alexander-Miller MA.

Viral Immunol. 2007 Spring;20(1):76-87.

PMID:
17425423
40.

Antiviral activity and RNA polymerase degradation following Hsp90 inhibition in a range of negative strand viruses.

Connor JH, McKenzie MO, Parks GD, Lyles DS.

Virology. 2007 May 25;362(1):109-19. Epub 2007 Jan 26.

41.
43.
45.

Modulation of CD8+ T cell avidity by increasing the turnover of viral antigen during infection.

Gray PM, Parks GD, Alexander-Miller MA.

Cell Immunol. 2004 Sep-Oct;231(1-2):14-9. Epub 2005 Jan 20.

PMID:
15919365
46.

Growth sensitivity of a recombinant simian virus 5 P/V mutant to type I interferon differs between tumor cell lines and normal primary cells.

Wansley EK, Dillon PJ, Gainey MD, Tam J, Cramer SD, Parks GD.

Virology. 2005 Apr 25;335(1):131-44.

47.

Altered function in CD8+ T cells following paramyxovirus infection of the respiratory tract.

Gray PM, Arimilli S, Palmer EM, Parks GD, Alexander-Miller MA.

J Virol. 2005 Mar;79(6):3339-49.

Supplemental Content

Loading ...
Support Center